Actavis-Allergan: Anatomy of a $66B Deal

The transcript discusses the merger between Allergan and Activist, highlighting the creation of a top ten pharmaceutical company. Jeff McCracken from Bloomberg provides insights into the merger's financial aspects, market reactions, and strategic decisions. The conversation also touches on R&D spending, company reputations, and the dynamics of the pharmaceutical industry, including past and potential partnerships.

What is the expected annual revenue generation from the merger between Allergan and Activist?

• $10 billion

• $15 billion

• $23 billion

• $30 billion

Why did Activist pay a higher share price than anticipated for Allergan?

• To gain a tax advantage

• To improve their R&D capabilities

• To increase their market share

• To prevent a rival bid from Valeant

What was one of the strategic benefits mentioned for the merger between Allergan and Activist?

• Increased R&D spending

• Lower tax rate

• Higher employee retention

• Expansion into new markets

What reputation does Valeant have in the pharmaceutical industry according to the discussion?

• Environmentally friendly

• Anti-science and low R&D spending

• Employee-centric

• Innovative and research-focused

What was a key concern for Allergan's CEO regarding the merger?

• Finding a partner other than Valeant

• Reducing R&D expenditure

• Increasing the workforce

• Expanding into new geographical regions